CG Oncology, Inc. (CGON) Analyst Ratings
CGON Analyst Consensus & Price Target
CG Oncology, Inc. (CGON) carries a consensus rating of Strong Buy from 10 analysts on record (Oct 24, 2024 to May 19, 2026): 8 bullish, 2 neutral, 0 bearish. The average price target is $54.14 (range $23.00 to $90.00), with wide disagreement among analysts. That implies +27.2% downside from the current price of $74.34. The price target on record has moved from $60.00 to $70.00 (+16.7%) between Oct 24, 2024 and Dec 11, 2025.
One vote per analyst, using each firm's most recent rating on record, not every historical reiteration counted separately.
Each analyst's most recent target on record, compared against where the stock actually trades. See how actual results have compared to estimates →
Is the average price target keeping pace with the stock, running ahead of it, or lagging behind? Compares the target's overall drift on record (across different analysts) to the stock's own move over the same window.
The stock has moved faster than analysts have updated their targets, targets may be playing catch-up.
Every rating on record, most recent first. "Next-close move" is the stock's own move from the prior close to the rating date's close, where price history lines up, a data point per event, not an averaged claim.
| Date | Analyst | Action | Rating | Price Target | Move |
|---|---|---|---|---|---|
| May 19, 2026 | Wolfe Research | Initiated | Peer Perform | — | +0.59% |
| Dec 11, 2025 | Wedbush | Initiated | Outperform | $70 | -0.31% |
| Nov 24, 2025 | Truist | Initiated | Buy | — | +2.64% |
| Oct 8, 2025 | Guggenheim | Initiated | Buy | $90 | +7.13% |
| Aug 19, 2025 | Piper Sandler | Initiated | Overweight | $55 | -2.18% |
| Jul 10, 2025 | Goldman | Resumed | Buy | $40 | +0.26% |
| May 2, 2025 | JP Morgan | Initiated | Overweight | $41 | +4.72% |
| Apr 16, 2025 | Scotiabank | Initiated | Sector Perform | $23 | +0.55% |
| Jan 7, 2025 | TD Cowen | Initiated | Buy | — | +4.34% |
| Oct 24, 2024 | UBS | Initiated | Buy | $60 | +2.36% |
What is the analyst consensus rating for CGON?
CG Oncology, Inc.'s consensus rating is Strong Buy, based on 10 analysts' most recent ratings on record: 8 bullish, 2 neutral, 0 bearish.
What is CGON's average analyst price target?
The average price target on record is $54.14, ranging from $23.00 to $90.00 across 7 analysts, wide disagreement. That implies -27.2% from the current price of $74.34.
Are analysts upgrading or downgrading CGON right now?
On record between Oct 24, 2024 and May 19, 2026: 0 upgrades, 0 downgrades, 9 new initiations, and 0 reiterations.
Are analyst price targets for CGON rising or falling?
The price target on record moved from $60.00 on Oct 24, 2024 to $70.00 on Dec 11, 2025, a change of +16.7%. This compares different analysts over time, not one analyst's revision.
How many analysts cover CGON?
10 analysts have rated CGON in the data on record, spanning Oct 24, 2024 to May 19, 2026.